Germany’s Merck KGaA is in advanced talks for a potential acquisition of SpringWorks Therapeutics, a U.S. biopharmaceutical ...

SpringWorks Therapeutics (SWTX) has announced that the U.S. Food and Drug Administration has approved GOMEKLI, a small molecule MEK inhibitor, for the treatment of adult and pediatric patients 2 years ...

BofA raised the firm’s price target on SpringWorks Therapeutics (SWTX) to $87 from $65 and keeps a Buy rating on the shares. Shares gained a ...

Wall Street expects a year-over-year increase in earnings on higher revenues when SpringWorks Therapeutics (SWTX) reports results for the quarter ended December 2024. While this widely-known consensus ...

SpringWorks Therapeutics (SWTX) has announced that the U.S. Food and Drug Administration has approved Gomekli, a small molecule MEK inhibitor, for the treatment of adult and pediatric patients 2 years ...

In a regulatory filing, SpringWorks Therapeutics (SWTX) disclosed that its CEO Saqim Islam sold 48K shares of common stock on February 10th in ...

SpringWorks Therapeutics (SWTX) may be acquired by Merck KGaA for $77 per share, representing a potential premium of 92% ...

Approval makes Gomekli the first treatment to be approved for both adults and pediatric patients for neurofibromatosis type 1 ...

Merck KGaA said it’s in advanced talks to purchase SpringWorks Therapeutics Inc., sending shares of the US cancer and rare ...

The U.S. Food and Drug Administration said on Tuesday it has approved SpringWorks Therapeutics' drug to treat a type of rare ...

SpringWorks Therapeutics ( NASDAQ: SWTX) soared ~40% after a report that Merck KGaA ( OTCPK:MKGAF) is in advanced discussions ...

The US Food and Drug Administration (FDA) has approved SpringWorks Therapeutics’ Gomekli (mirdametinib) to treat neurofibromatosis type 1 (NF1), a rare genetic disorder affecting approximately 100,000 ...